Hello and welcome to the Genmab conference call to discuss the Company's financial results for the first half of 2022. With me today to present these results is our CFO, Anthony Pagano.

And then, for the Q&A, we will be joined by our Chief Development Officer, Judith Klimovsky; our Chief Operating Officer, Anthony Mancini; and our Chief Medical Officer, Tahi Ahmadi. Let's move to slide 2.

As already said, we will be making forward-looking statements. So, please keep that in mind as we go through this call.

Let's move to slide 3. Genmab has an innovation-based culture, and collaborations and partnerships have always been part of our DNA.

During today's presentation, we will reference some of the products being developed under these strategic collaborations, and this slide acknowledges those relationships. Let's now move to slide 4.

Genmab has experienced significant growth over the past few years in all areas of our business. Based on this progress, our executive committee determined that it was time to look beyond our 2025 vision for the Company to see how we can continue to impact the lives of patients and the healthcare community even further into the future.

Working with a broad cross-functional team of Genmab colleagues, we created our updated core purpose and 2030 vision that you see here. The biggest change between our 2025 and our 2030 visions is the expansion in our focus from just cancer to cancer and other diseases.

We know that our antibody knowhow, assets and technologies can be applied to diseases outside of cancer. The approvals of Novartis’ Kesimpta in relapsing MS; and Horizon’s TEPEZZA in thyroid eye disease are proof of this.

So, while we will continue to create and develop new treatment concepts in oncology, we will remain open to other potential indications outside of cancer with the ultimate goal of improving the lives of as many people as possible through our innovative and differentiated antibody therapeutics. So now, let's take a look at some of the recent events that propelled us closer to our 2025 and our 2030 visions on the next slides, slide 5.

Genmab's innovative excellence and the hard work and commitment of our unstoppable team have been on display recently with a number of important events. At the end of June, we announced our intent to submit a BLA to the FDA for epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma.

In the second half of this year, subsequently in July, we announced that AbbVie will submit a conditional MAA to the EMA in Amsterdam for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, also in the second half of this year. And as a reminder of our collaboration details, Genmab and AbbVie share commercial responsibilities in the U.S.

and in Japan with AbbVie responsible for further global commercialization. The submissions will be supported by results from the LBCL cohort of the pivotal EPCORE NHL-1 study.

We and AbbVie announced the top line results from this study in April with primary results presented in a late-breaking oral presentation as part of the prestigious Presidential Symposium at the EHA conference in Vienna in June. The results from this study support our belief that epcoritamab has the potential to offer people living with LBCL and new therapeutic option with a manageable safety profile.

And we are very much looking forward to next steps. The late-breaking epcoritamab presentation at EHA was one of the many recent data presentations.

There were multiple epcoritamab poster presentations at ASCO with end course at EHA, highlighting data and a variety of treatment settings and hematological malignancies. In addition, we and our partner, Seagen, were pleased that several abstracts evaluating tisotumab vedotin and various tumor types were presented at ASCO.

These included an oral presentation of the innovaTV 205 study evaluating tisotumab vedotin in combination with carboplatin or pembrolizumab in first-line patients with recurrent or metastatic cervical cancer. The data presented recently for both epcoritamab and tisotumab vedotin are reflective of our commitment and the commitment of our partners to investigating these therapies across different lines and combinations.

Turning to our earlier stage pipeline. As it relates to DuoHexaBody-CD37, one of our assets with AbbVie, we will discontinue the co-development with AbbVie, and Genmab will continue development of this program on its own.

As we continue to explore this program, we look forward to providing you with further updates. I'm excited to announce an additional update to our product pipeline, a new antibody in the clinic by the end of this year for solid tumors, HexaBody-CD27, also known as GEN1053.

The development of this HexaBody-based product is part of our broadening partnership with BioNTech. And like GEN1046 and GEN1042, we will be co-developing this investigational medicine with BioNTech, 50-50.

The foundation of our differentiated product pipeline is our proprietary technologies. And I'm extremely pleased to share with you that our HexElect technology was recently featured in an article in the journal, Nature Biotechnology.

The HexElect technology is an approach to enhance the functional selectivity of therapeutic antibodies by making their activity dependent on clustering after binding to two different antigens expressed on the same target cell. The potential of this technology is another example of the innovative spirit of our world-class team.

I'm also enthusiastic about the fact that Janssen has announced a positive CHMP opinion for TECVAYLI or teclistamab, recommending conditional marketing authorization for the treatment of patients with relapsed and refractory multiple myeloma. Should TECVAYLI receives approval in either Europe or in the U.S.

where Janssen’s BLA is currently under review, there would then be six medicines on the markets that leverage Genmab's innovation and technology, including two medicines, Janssen’s RYBREVANT and TECVAYLI created using our proprietary DuoBody technology platform. As we look forward to regulatory submissions for epcoritamab, we are hopeful that medicines created with our DuoBody platform will continue to become new treatment options for people with unmatched medical needs.

DARZALEX continues to redefine the treatment of multiple myeloma with strong sales for the first half of the year as we reported $3,842 million in net sales by J&J, an increase of 37% over the first half of 2021, resulting in DKK 4,024 million in royalties to Genmab. This brings me to our new arbitration with Janssen relating to our daratumumab license agreement.

As we announced in the beginning of April, in the original arbitration, the tribunal ruled in favor of Janssen on the question as to whether Genmab is required to share Janssen's royalty payments to Halozyme for the technology used in the subcutaneous formulation of daratumumab. The tribunal based its ruling on the finding that DARZALEX FASPRO constitutes a new licensed product under the license agreement.

In the new arbitration, we are seeking an award of $405 million plus interest in accrued milestone payments for DARZALEX FASPRO and a declaration that we are entitled to a new 13-year royalty term from the date of DARZALEX FASPRO’s commercial sale. As the arbitration is confidential, outside of our disclosure obligations, we do not intend to comment further, and we look forward to our continued collaboration with Janssen.

I'm pleased to now hand over the call to Anthony Pagano to take you through our first half financial results. Anthony, the floor is yours.

Great. Thanks, Jan.

Let's move to slide 6. We continued to strengthen our foundation during the first half of 2022.

To start, we're on track for regulatory submissions for epco in both, the U.S. and Europe in the second half of this year.

And as we'll see, our H1 financials are exceptionally strong. We grew operating profit by 34%.

And importantly, we also increased recurring revenues by 86%. This was driven by strong royalties from DARZALEX and other approved medicines.

You'll remember, of course, that we didn't have any TEPEZZA revenues in Q1 of last year. Our strong balance sheet, growing recurring revenues and significant underlying profitability allow us to continue to invest in our business and our pipeline in a very focused and disciplined way.

Especially in the volatile times, the strength of our financial profile really stands out. And an important part of this has been to continue to build the team and our capabilities to enable us to succeed.

So, let's take a look at those revenues in a bit more detail on the next slide. We saw continued strong performance for DARZALEX in the first half of the year.

As you can see in the chart, overall, net sales grew by 37%. That's net sales of $3.84 billion, which translates to over DKK 4 billion in royalty revenue.

This exceptional growth was driven by continued strong market shares across all lines and continued uptake of the subcu formulation. So, DARZALEX remains a key driver of our revenue, as you can see on slide 8.

We grew total revenue to almost DKK 5.3 billion in H1. And as I've already highlighted, that included an 86% increase in our recurring revenue.

We've already spoken about DARZALEX and the very strong performance there. Turning to Kesimpta and TEPEZZA, we saw an increase of DKK 452 million in royalties compared to last year.

Taken together, this growth really illustrates the power of our recurring revenue. In fact, over 90% of our H1 revenue was recurring.

So, our revenue profile continues to get stronger. And we're taking our strong recurring revenue and investing in a highly focused way, as you can see on the next slide.

In line with our significant growth opportunities, total operating expenses grew 58% in the first half. In R&D, we've accelerated our investment into our product portfolio, especially the advancement of both epco and DuoBody-CD40x4-1BB.

We've also further strengthened the Genmab team to support our growth in commercialization and our expanding pipeline, and that includes supporting Tivdak and preparing for the filings and potential launch for epco. Finally, we're leveraging the AbbVie collaboration by utilizing their expertise and significant financial contributions to further expand and accelerate our partnership programs.

Now, let's take a look at our financials as a whole on slide 10. Here, you can see our summary P&L.

Revenue for the first half came in at approximately DKK 5.3 billion, and that's up 49% on last year. Total expenses were about $3.5 billion with 69% being R&D and 31% SG&A, and that brings us to a very strong operating profit of nearly $1.8 billion.

And for me, this result is particularly impressive given the context. And why do I say that?

Last year's H1 makes for a somewhat tough comparator as it included more than $700 million of milestone revenue. And this year, we've also increased our total investment in H1 by nearly DKK 1.3 billion.

And even considering these items, we still delivered a 34% increase in operating profit in H1. Moving to our net financial items.

Here, we have income of $1.3 billion, which was primarily driven by the same two partially offsetting items that we highlighted in Q1. First, we've got the strengthening of the U.S.

dollar against the Danish kroner positively impacting the value of our cash and investments. And on the other side of the ledger, we have losses on our marketable securities due to rising interest rates and some losses on our public equity investments that we made in conjunction with recent licensing deals.

Then, we have tax expense of DKK 745 million, which equates to an effective tax rate of 24%. And that brings us to our net profit of nearly DKK 2.4 billion.

So, as you can see, extremely strong financial performance for H1. Before we take a look at our improved guidance, I want to take just a minute to revisit our robust financial framework on the next slide.

First off, let's think about our revenue profile, which you can see on the left. At the beginning of 2020, DARZALEX was our only product on the market.

Today, we have five, and that provides us with expected recurring revenue growth of 53% in 2022, and there's a clear path to potentially expand the number of approved products with Janssen's BLA and MAA for teclistamab, and most excitingly, our planned submissions for epco later this year. Taken together, we expect significant cash inflows in the years to come.

Moving to the right, we continue to be focused on our investments as we evolve our organization for continued success, and right at the top of the list is accelerating and expanding epco. Based on the work we've done so far and the data we've seen, including the recent top line data, we're convinced, epco is a drug that has the potential to really make a difference for patients.

And epco is just one of the exciting opportunities that provide us with a compelling rationale for increasing our investment. As we told you before, if we want to seize these meaningful opportunities, we've got to invest, and that's exactly what we're doing.

So with that background, let's look at our improved guidance on slide 12. Driven by continued strong DARZALEX growth and the positive net impact of the strong U.S.

dollar, we raised our 2022 guidance earlier in the week. We now expect our revenue to be in a range of DKK 12 billion to DKK 13 billion, an increase of DKK 1 billion to both the bottom and top end of our range.

This increase is driven by higher DARZALEX royalties following the strong H1 performance. Here, we've increased our guidance for DARZALEX net sales to a range of $7.8 billion to $8.2 billion.

Our revenue also continues to be positively impacted by the U.S. dollar.

Turning to our investments. We remain focused on executing against our strategy and key priorities and creating long-term value.

Here, we are increasing our OpEx guidance to a range of DKK 7.6 billion to DKK 8.2 billion. This is driven by pipeline progression and accelerated epcoritamab launch readiness activities as well as the strong dollar.

Putting all this together, we're planning for substantial operating profit in a range of DKK 3.8 billion to DKK 5.4 billion. Now clearly, we've all seen a material appreciation of the dollar so far this year.

Taking this into account, we've updated our guidance range for the Danish kroner / U.S. dollar from 6.4 to 6.8 to reflect the year-to-date average through Q2 as well as consensus.

Overall, our increase in revenue is approximately 40% operational and 60% FX. And the increase in operating costs is roughly evenly split between operational items and FX.

And finally, to give you just a bit more color on foreign exchange, every 10-point move in the exchange rate relative to our guidance rate is worth around DKK 50 million in operating income for the balance of the year. Now, for my final slide, let me provide just a few closing remarks.

In summary, we've had an exceptional first half of 2022. We've created growing recurring revenue streams, and that gives us a strong backbone of significant underlying profitability.

And we continue to invest those revenues in a highly focused way to realize our vision and capitalize on the very significant growth opportunities in front of us. Now, on that note, I'm going to hand you back over to Jan to discuss our key priorities for 2022.

Thank you, Anthony. Let's move to slide 14.

Our key priorities are essential to our success, and we are making excellent progress. We are especially excited about the recent advancements for epcoritamab and in addition to the recent data and the announcements of our intent to submit a BLA in the U.S.

and AbbVie’s intent to submit a conditional MAA in Europe, a new Phase 3 study, EPCORE FL-1 is now listed on clinicaltrials.gov. The study will evaluate safety and efficacy of epcoritamab in combination with rituximab and lenalidomide or ORRs there, compared to -0alone, in patients with relapsed or refractory for lymphoma.

Together with AbbVie, we anticipate that this study will start in the second half of this year. We look forward to providing you with further updates on epcoritamab as well as on other clinical programs as Genmab continues to evolve into a leading fully integrated biotech innovation powerhouse.

So, let's now move to our final slide, slide 15. That ends our presentation of Genmab's first half 2022 financial results.

Operator, please open the call for questions.

Can I first just ask about the HexaBody-CD38, please? So, when can we expect the dara head-to-head trial to begin?

Is it fair to assume we won't really get an update from a data perspective until quite late into 2023? And just tied to that, any update you can provide on what you're seeing so far from the current data set that gives you confidence to begin that head-to-head study?

And my second question really is just in terms of epco and filing. 2H is quite a broad range.

We're in August. So, what more is really needed to file with FDA?

Are you in the process of putting the package together? Is there more data needed?

So, just any update there would be great. Thank you.

Thanks, Wimal, for the questions. I think, I can handle both of them myself.

HexaBody CD38, we are very excited about the data. You will see the dose escalation data this year, Wimal.

And we hope to start the head-to-head against subcu dara near the end of this year. So, no data will be there this year.

And indeed, I think end of '23 for the head-to-head data is probably the right approximation. Then for the epcoritamab filing in the second half, we have all the data, and we are now basically working on the filing as we speak, Wimal, and we hope to actually finalize that filing in the coming months, literally.

That's probably all we can say on the timing.

A couple for me. First one, on your updated 2030 vision, can you provide any more granularity on your plans outside of oncology?

And then, second question, when could investors see additional clinical data for GEN1046 and 1042? Will these be in the second half of this year or not?

Thanks, Jonathan, for the questions. I will ask Judith Klimovsky to basically give it a start on both of your questions, and then I can see what I can add.

Judith, the floor is yours.

Yes. So to answer the third question on areas beyond oncology is in serious diseases where our technologies and antibody expertise can make a difference.

So, we are assessing actively as we speak. There could be low-hanging fruits.

And as Jan mentioned some examples of tepro, Kesimpta, even the [indiscernible]. So, we exploring this actively as we speak.

So, we cannot provide more granularity at this point. With regard to the second question, we are committed to deliver the data to come to a proof-of-concept for GEN1046 and/or GEN1042.

We are actively enrolling. And as you know, we are a very data-driven company.

We are committed to gather this data by the end of the year. The opportunity to present, we are actively assessing vis-à-vis the time lines for the different conventions, but we feel committed to our -- to our goal to present this data by the end of the year.

Thanks, Judith. I think nothing to add, Jonathan, for now, but thanks for the questions.

A couple of pipeline and then just one financial. Just a follow-up on 1042 and 1046.

Wondering if you could just provide more color where you are with the program. So, my interpretation of prior commentary had been that you've obviously got multiple combinations ongoing with different sequences.

And there have been signs of initial efficacy and really trying to work what combinations are giving you the best durability of response vis-à-vis safety. So, is that interpretation fair?

And just any color you can provide us where you are on the path to finding the right combination and sequence? Second pipeline is the CD37.

Just any color as to what AbbVie saw to hand that asset to you? And then, just one financial for Anthony.

Just given the variability of milestone income, just any color you can give us as to how to think about milestone revenue expectations this year within guidance? And obviously, any color you can give on that question that would be super helpful.

Thank you.

Thanks, Sachin, for the questions. What I will do is I will hand the first question on 1042, 1046 to Tahi and also ask Tahi basically comment further on the AbbVie decision, if possible.

And then Anthony Pagano can pick up on the milestone and epco questions. Tahi, the floor is yours, Tahi.

Thank you, Jan. Well, I mean, this is going to be relatively short.

I think beyond what Judith earlier said on 1042, 1046, I don't think we're in a position to give any more clarity on the data that we're generating. Obviously, you can tell from clinicaltrial.gov and commentary on our end as you correctly summarized that we are generating combination data, both in combination with checkpoint inhibitor as well as combination checkpoint inhibitor in chemotherapy in a variety of solid tumors.

And once we have the data, we will make the decisions and communicate the decisions and certainly submit at some -- presenting what data we have that is meaningful towards the end of the year for the two programs. I think that's all we can say potentially to 1046.

As it relates to 1037, I think there's two things to say, A, dose escalation has not yet completed. And as to AbbVie made the decisions that they made, I think they're probably in a better position to comment on that.

Thanks, Thai. Then also to Anthony Pagano.

Maybe sort of stepping back and sort of reminding you of our original 2022 guidance at the beginning of the year. And here we highlighted -- we broke down our revenue between recurring items and nonrecurring items.

And as a reminder, at the beginning of the year, we said around DKK 1.7 billion to DKK 1.8 billion was nonrecurring and that's where the milestones are located. I would say, broadly speaking, that's still the right way to be thinking about nonrecurring revenue in aggregate.

I'm zooming in on epco. Again, consistent with what we said at the beginning of the year, we continue to add approximately DKK 500 million of epco milestones in our 2022 guidance, which is -- this amount, this DKK 500 million is primarily related to the filing and acceptance of a regulatory submission in a single territory.

Now, I think this is probably what you're getting at. In the event, we successfully file and get acceptance in more territories -- again, with acceptance being the trigger, we would be entitled to an additional milestone.

So, hopefully, that gives you a little bit more color, Sachin.

Thank you very much. Can I just take one additional for Tahi, just to -- I understand no additional color, but perhaps you could just comment at a much higher level, and where's your level of confidence based on what you're seeing, either or 1042, 1046 will be Phase 3 ready by the end of this year?

I don’t think -- we can comment one way or the other. So, we’re generating the data, we’re enrolling patients, we're looking at the signal.

And I think in the past, we've been very aggressive in making these decisions very early on the small datasets. Once we have the confidence, we will communicate that to you in the appropriate form.

We have some confidence that we will have data by the end of the year that -- certainly critical next steps -- are the next steps maybe.

So, Jan, I know you don't want to talk too much about the new arbitration mandate, but maybe you could tell us what sort of a timeline we should expect for this. So, it should be similar to the previous arbitration?

And also, is there a completely new arbitration panel for this? Then, I have a follow-up.

Thanks Asthika. We can say very limited amount of information.

But I can tell you that we think this is a much simpler, much easier arbitration, basically centering around, is FASPRO a new product or not. And if it's a new product, then it has consequences.

So, the timelines are inherently uncertain, but we would certainly hope that this will develop a lot more quickly than the previous arbitration, Asthika. But we cannot give any guarantee because it's up to the judges and the panel to determine the timelines.

Got it. That’s helpful.

Then maybe just going back to GEN3009. Let's assume that you've completed enrollment in the monotherapy dose escalation.

And then, I was just wondering how far along are you on the recruitment for the epco -- on the combo cohort?

I think I can answer this one, Asthika. We are finalizing the dose escalation.

So, we are not yet completely done on the dosing, we’re testing different doses still. And we have not yet started the combination with epco.

We hope to start that in the coming time, once we know what the recommended Phase 2 dose is.

And Jan, how confident are you that this could be a drug, given that AbbVie has stepped away from it?

Yes. I should probably not to mention that any further, as I think Tahi has already explained, we are very much data driven company, rational company.

The molecule is clearly active. We have already said last year in December that there is a good safety profile here.

But I think it's probably premature to comment on that. We will inform you once we know, and we are very busy with the program.

Until the end of this year or so AbbVie will co-sponsor the program, will pay for 50% of the expenses, and they have taken a portfolio decision. That's up to them.

And as Tahi already said, I think AbbVie needs to comment on that probably further. But we are pretty enthusiastic about what we see preclinically and early clinically to tell you more once we have analyzed all the data.

One question on CD40x4-1BB programs, so increasing investment. So, could we read that you're more excited or more prioritizing CD40 -- the PD-L1x4-1BB, because only heard about increased one of them?

And can you broadly break down how much of the extra -- epco versus the 4-1BB bispecific? So, that’s the first question, please.

And second question -- on track for epco for relapsed/refractory DLBCL, but can you determine where are we on relapsed/refractory FL timelines? What's your base case and when you might be able to follow?

So actually, for CD40-B, we are very excited about that molecule. And we are expanding a number of trials, is another Phase 1/2 trial, where we tested in combination with radiotherapy, with or without pembro.

So, we are very excited about that molecule, as you already said before, James. I think as it relates to the spend on this program versus epcoritamab, I will ask Anthony Pagano to comment on that in a second.

But maybe I can first ask Judith on the FL timeline. So, Judith, you know I think quite precisely where we are with the follicular lymphoma.

Maybe you can give James some color on that.

So, as you know, for follicular lymphoma, in addition to enrolling the patients, the median follow-up needs to be a little bit longer given the nature of the disease. So, we are assessing actively this median follow-up to have a more clear picture when the filing would be possible.

So, we will -- when we are ready to disclose, we will. But as you understand that this is different.

So, it needs a different follow-up time.

And then, Anthony Pagano, maybe you can give James a bit of color on the epco spend says the CD40x4-1BB, extra stand, because we’re starting new activities. Let's see what you're willing to share here with James.

Yes. I guess, maybe sort of like step back and think about it overall, we see a nice increase in the overall progression of our pipeline.

And then, that translates into the increased investment as you would have seen. We've increased our R&D investment, roughly speaking from DKK 1.8 billion in H1 of last year, up to DKK 2.4 billion this year.

And I would say the two biggest drivers, if I look at that DKK 666 million increase, the two biggest drivers are going to be epcoritamab, and then the build out of really supporting the overall progression of our research activities and progression of our clinical development pipeline and assorted manufacturing activity. So, as you just probably heard, the two biggest drivers are epco and build out of the team.

So then obviously, CD40x4-1BB would rank behind that -- I would say, it ranks behind certainly epcoritamab by a fair margin at this point. Again, you shouldn't read anything into this other than where we're at in the overall stage of the development of the program.

Hi. This is Paul on for Michael.

Thanks for taking our questions. Just a few on your recent expanded partnership with BioNTech.

I guess, first, was there anything that was observed in your ongoing clinical HexaBody programs or partnered DuoBody programs that sort of triggered this deal? And then, are there any pre-specified number of monospecific candidates that you plan to nominate under the collaboration?

And then lastly, any additional color on how the HexaBody platform might position you to address the CD27 target?

Thanks, Paul. Good questions.

We are very excited about the BioNTech partnership. We are working on a number of programs.

So, there are already candidates selected for HexaBody approaches beyond CD27. But, I will ask Tahi who's actually overseeing part of that work with BioNTech to give you some further reflection and comments on your questions.

Tahi?

Thank you, Jan. So, I’ll try.

So, I would first say that the collaboration with BioNTech has been one that's been ongoing for now several years and has been an extremely fruitful collaborative collaboration. And as we have worked together on a multitude of targets and more and more about how to better address them, and this has led now to the expansion of this collaboration to also into excellent organization as a Genmab developed technology for certain targets that are part of our collaboration.

The first one that is going to the clinic, as Jan was saying, is CD27, maybe very clearly, and we will show that data and presented to you in the near future, have preclinical evidence that our HexaBody technology, the ability to hexamerize leads to a significantly stronger signal than comparative antibodies, including those that are in clinical development already. And so, that's where our condition comes that this could be a differentiated approach to this particular target.

And obviously, that insight also translates to potential other targets. And there are, as Jan already said, other programs that are in development in this collaboration with BioNTech, which is an extremely fruitful and efficient and effective collaboration.

Thanks, Tahi. Thank you, Paul, for the questions.

I’m speaking on behalf of Matthew Harrison. So, I have two questions.

One is on epco. So, what do you think are the key factors around commercialization?

Because we have recently seen a lot of late-line DLBCL launches that have plateaued after a few quarters. So, with that information, what do you think that has told you about the market potential in this particular disease?

And then, the second question is about the 4-1BB programs later this year. What bar in the lung cancer expansion cohort is enough in terms of the overall response rate, or would you need to see mPFS?

Thanks.

Thanks, Chris. I will hand the first question over to Anthony Mancini to talk a bit about market potential of the -- of epcoritamab and the potential in commercialization there.

And then, the second question probably to Judith to speak a bit more about lung cancer and the bar for the 4-1BB programs. Anthony, floor is yours.

Thanks, Jan, and thanks, Chris, for the question. Just to provide some context on the commercial potential, the initial addressable patient population in DLBCL across U.S., Europe, and Japan is about 9,000 patients in late lines.

It steps up quite significantly in the second line and in the front line. But what's really important here is just if I focus on the U.S.

market is the site of care dynamics. And today, they're such that LBCL is largely treated in the community in the first- and second-line setting.

And in later lines, although more therapies have recently become available, what we're hearing from our customers is that there's quite a large degree of dissatisfaction in that setting. And the patients more often refer to a hospital or academic setting.

And it's clearly driven by the fact that more effective options are only available there. What we also hear pretty consistently from treating clinicians is that off-the-shelf therapies that can deliver the right balance of efficacy and safety and also have the accessibility of an off-the-shelf subcu administration, if those types of therapies were available that they would continue to treat these patients in the later line settings in the community.

And frankly, a large portion of potential patients that are referred do not get the therapies that they're hoping to get it in an academic setting. So, we still think that epcoritamab offers the potential to have -- to be best-in-class and to have the right balance of efficacy and safety.

That's certainly what we've observed thus far. And with the accessibility of a subcu administration, we still see meaningful potential opportunities in the long term, not just in the late line settings, but particularly as we continue to explore in earlier lines and across B-cell malignancies.

So, I think I'll leave it at that, Chris.

Thanks, Anthony. Then maybe, Judith, maybe you can say a bit more about the bar and lung cancer after checkpoint inhibitors, if you are able to do that for the 4-1BB programs.

Yes. Thank you.

So, I think that the question is alluding the study 04 for 1046, which is a study as Jan mentioned in second third line non-small cell cancer after patients failed or exhausted checkpoint inhibitors and doublet chemo. So, let's start with the unmet medical need.

As checkpoint plus chemo are moving to the first line for most of the patients or sequential on some, there is a huge unmet medical need for patients that exhaust these main options. That vary population is the data that we presented at SITC and not last year, but the prior one where 1046 as a single agent lived one order of 17%, short lasting mostly but an order of 17%.

The bar in that setting is very low. Patients are treated with docetaxel, usually if they can tolerate.

And as we know, other try that space with no activity or single digit activity at the most. So, this is the study that we are now doing with 1046 in combination with pembro or as a single agent, and the bar is driven by response rate.

But of course, durability as well, because what we want is improved survival that should be the level. So, I won't give you the bar, but you can -- it's huge and may become very poorly served with a current option with docetaxel.

And the bar for other small studies, more current contemporaneous data on docetaxel is in the single digit order.

Hi, this is Jenna [ph] on for Yaron. Thanks for taking my question.

I actually have a few questions on DARZALEX. So, given previous CASSIOPEIA data showing that DARZALEX maintenance improves PFS over observation, do you think that DARZALEX is actually going to become a key component of maintenance therapy as well?

And also along those lines, what's your expected timeline for initial data from the AURIGA trial? Secondly, I see that you're also testing DARZALEX and newly diagnosed multiple myeloma as part of the VRd quadruplet and transplant eligible and non-eligible myeloma patients.

Could you give some guidance as to when we could see that data from CEPHEUS and PERSEUS?

I will ask Tahi to give perspective on -- or to give a perspective and answer on to both of your questions. Tahi?

Well, I would say some of these questions are probably better asked to J&J, frankly, because they are in charge of these studies. So, they have a better sense on the timeline, so when they are suspected to read out, particularly for the VRd combinations, which are studies that are conducted by Janssen.

So, I'm not sure we are in position to comment on timelines of that. But in terms -- I think you’re right that DARZALEX has shown across a multitude of studies in different settings that it is a drug that in myeloma setting, when given continuously until progression does have an impact on PFS, and actually also on -- as certainly some of the data studies that are shown.

Thanks, Tahi. What I can say is that while in ct.gov, we can see that the CEPHEUS Phase 3 trial, it's of course, it's event driven, that it has an estimated completion date of September 22.

We need to leave it that and then the total information needs to come from our partner, Janssen, as Tahi already said.

Thanks so much for squeezing me in, Elizabeth Walton from Credit Suisse. I just have a couple of questions left.

Firstly, one on costs. I'm curious, if you can provide us any color on the relative spend to SG&A and R&D.

We saw a meaningful step-up in your SG&A spending this quarter versus expectations. How should we think about that going forward?

Is there much more that needs to be done to prep for epco? And then secondly, on DARZALEX.

Curious on your view on the conversion rate from the intravenous to the subcutaneous formulation. J&J told us in their results, it's about 85% some companies in the U.S.

and 80% in Europe. How does that track versus your internal expectations?

Thanks, Elizabeth, for the questions. I propose that the cost question goes to Anthony Pagano and that's the -- and that Anthony Mancini gives us a bit of perspective on how we think about IV to a subcu conversion as we see it not only in the States, but also outside of the States.

And maybe Anthony Pagano can start.

Sure. Happy to do so.

Thanks for the question, Elizabeth. Yes, you're right.

As our business evolves, we're grounded in investing for what makes sense for Genmab, right? So historically, think about it, everything was going into R&D.

And as we got closer to the filing last year and then the launch of TIVDAK, obviously, we ramped up that investment in a very focused way together with our partner. So what you're seeing now for TIVDAK in particular, whereas in H1 last year, you wouldn't have had a ton of cost for TIVDAK and H1, I would say a fully loaded, let's call it, cost structure for TIVDAK in our H1 P&L.

And that will continue moving forward in the second half of this year and also into 2023. Now for epco, I would say beginning of last year, getting into H1 this year, we've started launch readiness activities for epcoritamab in earnest.

And now following the positive readout of data that we saw in April and now with the -- our announcement of the intent to file, particularly in the U.S., we have to invest for success here. So we are starting to ramp up, as you've just alluded to, our investment in SG&A in H1, and that will continue here in the back half of next year and also into next year.

But again, a really focused and disciplined way here to make sure that we really are well positioned to let epcoritamab shine in the marketplace, should it be approved. And I think just something wrapping this all together, just with the overall expansion of our really exciting clinical pipeline and the 2 commercial drivers that I just highlighted, there is an increase in need to invest in systems, whether it be CRM, ERP, enhanced compliance functions is really round out and make sure that Genmab as a whole is really well positioned to support the growth and manage risk appropriately along the way.

Hopefully, Elizabeth, that gives you a little bit of color. And I think Anthony Mancini can take on the other question.

Yes. Thanks, Anthony, and thanks to Elizabeth for the question on conversion rate.

The way we think about it is that really the availability of the subcutaneous formulation in around the world really was a clear driver of strong share performance. And as J&J outlined on their call, it accounts for over 80% in terms of usage, in terms of weekly gross sales in the U.S.

and around 80% in Europe. And what I would say is that it's largely in line with our expectations.

I think where we continue to applaud Janssen's execution in Europe and rest of world, in particular, is the rapid availability and access to the subcu formulation has really driven frontline in particular, share gain. So if I just contextualize that a little bit, the overall share gains are impressive in both the EU5 and in the U.S.

So just looking at IQVIA brand impact data ending at the end of the quarter, there was about a 6% absolute overall share gain in the U.S., about a 13% absolute share gain in the EU5. But when we look at the frontline share, we saw an absolute share gain in the U.S.

of 12%, which is impressive, but an even more impressive 22% improvement in share points in this new frontline setting in the EU5. So we think that's driven by strong execution resonance to the overall survival benefit and the availability of subcu, which, as you know well, leads to facilitate earlier usage due to its convenience, efficacy being the same as IV and of course, the safety benefits and convenience benefits that exist.

So hopefully, that covers that.

Thanks, Anthony. Thanks, Anthony and Elizabeth.

Let's go on the next question.

So, I'd like to ask a question on epco commercialization in a different way, if I may. So from the discussions you have with physicians so far, how they view the data for epco and in particular, how it compares versus glofitamab from Roche?

And the latest data you shared that we have points to a slightly better safety and efficacy for epco. So I'm just keen to understand whether this is something you hear from physicians or at this point in time?

Or perhaps both drugs at this point are give more or less comparable? And my second question is, I noticed on ClinicalTrials.gov that you have initiated a Phase 2 safety study for epco.

And is there something you need to have in place before you submit to the BLA application? Is it to support or strengthen the data?

Or there's a safety concern here? I'm just wondering of the rationale for this.

Thanks, Zoe, for the questions. I propose that definitely Judith will speak a bit more about epco versus glofi and also the trial, the safety trial in the context of the filing and the route forward for epco.

But maybe, Anthony Mancini, you can also give some perspective on commercialization, so we want to hear of epco versus other CD3/CD20 bispecifics. Anthony?

Zoe, do you want me to start? Okay.

But look, I think in line with what I said earlier in terms of what we're hearing from clinicians is the desire to treat these patients. And we believe based on the data that we've seen the LBCL cohort of the epco and NHL-1 study, which were shared at the EHA Presidential show that really epco now offers a balance between efficacy, safety and the accessibility of subcu administration.

And what we're hearing from clinicians is that, that matters. So we feel we will have -- that there are differences between the agents, and we're looking forward to have the opportunity to showcase those going forward.

So maybe I'll pass it to Judith for the other comparators.

Thank you, Anthony. So a cross-study comparisons are limited by the different natures of the populations enrolled.

Although you might have similar eligibility criteria, there are nuances that can impact the results. For example, when you see the glofi, it seems the same population.

However, the median lines of treatment with epco is 3.5 versus 3. The transform follicular population, super difficult to treat is 29% for epco and 17% for glofi and so on so forth.

So you see difference. So you cannot compare because you will be doing by a comparisons influenced by factors that you don't control.

Having said that, when we put vis-à-vis the data on epco vis-à-vis glofi and some other merchant data, we see that numerically, there is a trend for better efficacy, better safety and last but not least, advantage of subcutaneous and there's a need of inotuzumab or any preparation for the patient. So as the whole package, we see that is very robust to support the whole value proposition for epco.

And I mean a testament -- I mean, I am a development person, but I'm telling you when studies enroll fast, it's a good signal of the belief or confidence in an investigational agent. And as you see -- as you have seen, our program progressed, you can guess that enrollment has been -- we had the support of the medical community for enrollment.

This is with regard to comparative data. With regard to the outpatient care is further request, is some data that we wanted to generate, to give more -- to have this data to help the community centers or every physician that want to have potentially when it's approved, prescribe epco that we have the whole state of data and information to help data, help physicians understand how to use the drug.

So this is the reason, it's a very nice study, which is exploring epco in a fully outpatient basis.

Thank you, Judith. Thanks, Zoe, for the questions -- excellent questions.

Let's move on to the next one.

This is Luke Chumley [ph] on for Etzer Darout. I guess on the GEN1053 asset with BioNTech, you said that you're going to be looking at solid tumors.

Do you have any more clarity on that? Like, are there specific indications that you're going for?

Or are you going for any tumor-agnostic approach?

Tahi, can you -- are you willing to provide some further color on that?

Sure. So I mean, what I would say to the question is the first question that we need to address in our first in human trial will be the biology CD27.

That's essentially a tumor-agnostic biology. And then we can, in the next subsequent session identify the opportunity, which may not necessarily be only restricted to solid tumors, if indeed, we initially biology that we have preclinically seen on the CD27 biology particularly the increase of CdA T-cells to make alignments and the activations are.

Then we can have our second step questions around what is the profit setting for interrogating, that particular biology is or in what combination.

Thanks, Tahi. I think, operator, I think we lost them.

All right. Thank you very much for the question.

Operator, back to you.

So, thank you for calling in today to discuss Genmab's financial results for the first half of 2022. And if you have any additional questions, please reach out to our Investor Relations team.

We hope you all stay safe, remain healthy and very much look forward to speaking with you all again soon.